
- /
- Supported exchanges
- / US
- / VALN.NASDAQ
Valneva SE ADR (VALN NASDAQ) stock market data APIs
Valneva SE ADR Financial Data Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Valneva SE ADR data using free add-ons & libraries
Get Valneva SE ADR Fundamental Data
Valneva SE ADR Fundamental data includes:
- Net Revenue: 186 M
- EBITDA: -135 784 752
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.2005
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Valneva SE ADR News

CSL to replace Bavarian Nordic in Valneva’s vaccine deal for Germany
[Tip of fountain pen writing] Martin Barraud * French biotech Valneva SE (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]) announced Thursday a partnership with Australian company CSL Limited (O...


Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
VALNEVA Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the wor...

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
VALNEVA Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Di...

Valneva Selects CliniOps as the Technology Partner for Multiple Post-Marketing Studies to Support the IXCHIQ Chikungunya Vaccination Program in Brazil
This collaboration underscores CliniOps’ continued mission to transform clinical research through smart technologies, enabling equitable access, operational efficiency, and robust data quality, even...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.